. . .Our methodology will have the most rapid impact for chemicals that are currently produced on demand in small batches and that occupy a gap in the market where the demand for a product is sufficient for it to be commercially viable but insufficient to justify plant-scale production. This gap lies between the high cost of bench-scale versus reactor- scale synthesis, and thus the digitization benefit of compounds in this zone is high

OUTLOOK ’17: US ABS demand to begin on strong note US acrylonitrile-butadiene-styrene (ABS) demand in the first quarter of 2017 is expected to be bolstered by higher Asian ABS prices. ABS demand typically drops off in November and December due to seasonality factors, but higher prices in Asia began impacting demand for US product in December.

The Acquisition will increase the Group’s momentum towards its 40 per cent. operating margin target. The Group has identified a number of cost synergies in the business and will also benefit from greater investment management and distribution capacity following completion of the transaction.

OUTLOOK ’17: US TDI rise on supply, MDI stay steady US prices for isocyanates are mixed heading into the new year, with prices for toluene di-isocyanate (TDI) shooting up on global supply tightness while prices for methyl di-p-phenylene isocyanate (MDI) are following a mostly steady trend. In the TDI market, tight supplies have resulted in significant upward movement in major global markets.

The Board continues to progress its transformation strategy and, following his appointment as CEO, Phillip has been tasked with delivering an accelerated path to growth and profitability of the Group, for the benefit of all of the Company’s stakeholders. Fee income (CIB retainers, Private Wealth management and advice fees) is now running at approximately £1.3 million a month, representing nearly 55% of our total monthly revenue and provides a strong platform from which to continue to build. Whilst there remains much to be achieved, I believe that the foundations are being put in place to deliver growth across both divisions.

North Carolina Health News: Health Insurer Promotes Health And Builds Their Brand Through Basketball Dozens of children in bright blue t-shirts roared and bounced across the bleachers. Meanwhile, a handful of breakdancers somersaulted across the gym floor and froze in gravity-defying holds. A minute later, the purpose of the last week’s rally in Charlotte became clear when a rapper yelled “We’re getting asthma under con….” and the school-age children screamed “troll!” (Duong, 10/5)

OUTLOOK ’17: Latin America caustic soda soft but steady he Latin America caustic soda market is projected as steady but soft in the face of troubled economies in South America. Demand in Latin America from major consuming industries such as pulp/paper, alumina, and soaps and detergents is stable though not spectacular.

Thanks. Good morning, and congratulations on the results. Wendell, a bit of an open-ended question for you on Optical. So, you obviously are growing a lot faster than market, so I was curious if you could maybe, one, talk about some of the key end markets you’re serving and what you’re expecting in terms of spending there; and then what are the key innovations that are driving the outgrowth in, say, like data center broadband and wireless? Thanks.

The Washington Post: Study: Lingering Illnesses Can Trouble Women For Years After Assault, Workplace Harassment Women can experience lingering health problems years after workplace sexual harassment or sexual assault, a new study finds. These health problems can include high blood pressure, poor-quality sleep, anxiety and symptoms of depression, the researchers found after doing medical exams of about 300 women. (Geggel, 10/6)

From a regulatory/safety standpoint, this is a terrible idea as one would still need QC oversight and spec setting on regulated starting materials (as well as reagents/solvents), control systems to prevent deviations from acceptable operating space, in-process analytics, release criteria with validated assays to ensure product quality (as well as no deadly impurities are present), and of course correct crystal form and particle size that is suitable for formulating. All of these analytical needs and testing as well as formulating immediately swamp any perceived benefit/cost associated with 3D printing a simple reaction vessel. These regulations and tests exist for very good reasons, namely patient safety by ensuring product quality and hence provide a very strong rationale for centralized production (not to mention the economy of scale and reliable supply chains on key RMs). I find that all of the authors claims to utility are laughable at best, but kudos to both his use of buzzwords and ability to generate hype. Science should also be ashamed…did any actual, working industrial chemists (or even better, chemical engineers) with knowledge of pharmaceutical production actually review this paper? I could keep going with both criticism of the actual work as well as its stated potential…but my typing fingers grow weary.

The Company and Livingbridge VC today entered into a vendor placing agreement with the Banks (“the Vendor Placing Agreement”). Pursuant to the Vendor Placing Agreement, the Banks have secured purchasers of the Placing Shares at the Placing Price and accordingly have raised approximately £11.7 million.

The randomised, double-blind, placebo-controlled study was conducted in two parts, with a single-dose phase and a multiple-dose phase and treated a total of 18 subjects aged 16-18 with Crohn’s disease. In the single-dose phase, eight subjects were given a single dose of either Thetanix or placebo. In the multiple-dose phase, 10 subjects were given either Thetanix or placebo twice daily for seven consecutive days.